Marcel van den Brink, MD, PhD

Lab Head

Marcel van den Brink, MD, PhD

Office Phone


Lab Phone



University of Leiden, The Netherlands


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Marcel van den Brink discloses the following relationships and financial interests:

  • Ceramedix
    Provision of Services
  • DKMS
    Fiduciary Role/Position; Provision of Services
  • Da Volterra
    Provision of Services
  • Garuda Therapeutics
    Provision of Services
  • GlaxoSmithKline
    Provision of Services
  • Juno Therapeutics
    Intellectual Property Rights
  • King Faisal Specialist Hospital & Research Centre
    Provision of Services
  • LyGenesis, Inc.
    Provision of Services
  • MJH Life Sciences
    Provision of Services
  • Notch Therapeutics
    Ownership / Equity Interests; Provision of Services
  • Pluto Immunotherapeutics
    Ownership / Equity Interests; Provision of Services (uncompensated)
  • Priothera Limited
    Provision of Services
  • Rheos Medicines, Inc
    Provision of Services
  • Seres Therapeutics
    Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
  • Smart Immune SAS
    Provision of Services (uncompensated)
  • WindMIL Therapeutics, Inc.
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures